The Role of NIH in Drug Development Innovation and its Impact on Patient Access: A Workshop

Type: Stand Alone Workshop
Topics: Public Health, Quality and Patient Safety, Health Services, Coverage, and Access
Board: Board on Health Care Services

Activity Description

An ad hoc committee planned and hosted a 1.5-day public workshop to facilitate discussion focused on the translation of federal investments in biomedical science to innovation in drug development and how the public benefits from that investment in terms of drug pricing and access. The meeting featured invited presentations and panel discussions on topics including:

- how federal funding for biomedical research, particularly via NIH, has contributed to new drug development, both directly and indirectly;

- the pricing of drugs that have benefited from federal investments in biomedical science;

- the role of technology and patent transfer to and from entrepreneurial organizations associated with NIH-funded research;

- potential ways to better track, quantify, and document NIH contributions to innovation in drug development; and

- potential strategies and policies to facilitate the translation of federally-funded biomedical research into innovations in drug development and to help ensure that the public has affordable access to those innovative medicines.

The planning committee developed the agenda, selected and invited subject matter experts and discussants, and moderated the discussions. A proceedings of the event will be prepared in accordance with institutional guidelines.


Speakers, Moderators, and Panelists:
Tahir Amin, Initiative for Medicines, Access & Knowledge (I-MAK), Inc.
Christopher Austin, National Center for Advancing Translational Sciences, NIH
Jeff Bingaman, Former U.S. Senator, New Mexico
Margaret Blume-Kohout, Gettysburg College
Tanisha Carino, FasterCures, Milken Institute
Amitabh Chandra, Harvard University
Christine Colvis, National center for Advancing Translational Sciences, NIH
Patricia Danzon, University of Pennsylvania
David Dilts, Vanderbuilt University and Oregon Health & Science University
Steven Galson, Amgen
Lynn Hudson, Critical Path Institute
Aaron Kesselheim, Harvard Medical School and Brigham and Women's Hospital
Danielle Li, MIT Sloan School of Management
Mark McClellan, Duke University
Steve Merrill, Duke Law Center for Innovation Policy
David Mitchell, Patients for Affordable Drugs
Jennifer Moore, Institute for Medicaid Innovation and University of Michigan Medical School
Chuck Na, National Institute of Standards and Technology
Kevin Outterson, Boston University School of Law
Leigh Purvis, AARP Public Policy Institute
Arti Rai, Duke Law School
Terry Rauch, United States Department of Defense
Bhaven Sampat, Columbia University
Ameet Sarpatwari, Harvard Medical School and Brigham and Women's Hospital
Ashley Stevens, Focus IP Group, LLC
John Thomas, Georgetown University
Reed Tuckson, Tuckson Health Connections
Doug Wirth, Amida Care
Janet Woodcock, Center for Drug Evaluation and Research, FDA

For more information

Previous Meetings for this Activity